AP
APN.JSE Aspen Pharmacare Holdings Ltd
- Market cap
- ZAC 69.2B
- P/E
- -
- P/B
- 86.07x
- ROE
- 3.3%
- Dividend yield
- 1.46%
- Fundamental score
- 1.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is APN.JSE undervalued?
Graham numberThe Graham number of Aspen Pharmacare Holdings Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aspen Pharmacare Holdings Ltd fundamental analysis
9 of 22 checks passedROE 0/2
Low return on equity (3.3%), below 10%.
ROA 0/1
Return on assets (2.4%) is below the industry median (3.8%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (344.4%) is above the 5-year average (-10.8% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (344.4%) is above the industry median (14.7%).
Revenue Growth 0/2
Revenue shrank 5.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (19.4%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is 3.5x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.9x) is below the industry median (1.5x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield cannot be calculated.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 35.5%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Aspen Pharmacare Holdings Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aspen Pharmacare Holdings Ltd
Aspen Pharmacare Holdings Limited, together with its subsidiaries, operates as a specialty and branded pharmaceutical company in Africa, the Middle East, Europe, CIS, Australasia, Asia, and the Americas. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers sterile products in injectable form primarily administered in hospitals and prescribed and administered by physicians or in a retail pharmacy environment for therapeutic areas, such…
Full company profileAspen Pharmacare Holdings Ltd financial statements
Aspen Pharmacare Holdings Ltd annual financial statements (ZAR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 41.2B | 42.6B | 38.9B | 38.6B | 37.8B | 38.6B | 40.7B | 44.7B | 43.4B | 34.9B |
| Gross Profit | 19.9B | 21.6B | 19.7B | 19.3B | 17.8B | 18.3B | 18.4B | 19.4B | 19.1B | 14.1B |
| Operating Income | 8.30B | 9.24B | 4.81B | 7.06B | 7.07B | 8.67B | 7.82B | 7.00B | 1.44B | 5.40B |
| EBITDA | 9.50B | 10.1B | 5.65B | 7.32B | 8.68B | 10.6B | 9.67B | 9.91B | 3.62B | 7.32B |
| Net Income | 5.10B | 6.01B | 6.46B | 4.66B | 4.81B | 6.49B | 5.23B | 4.40B | -1.08B | 2.65B |
| EPS | 11 | 13 | 14 | 10 | 11 | 14 | 12 | 9.91 | -2.44 | 5.96 |
| Balance Sheet | ||||||||||
| Total Assets | 116B | 133B | 122B | 133B | 110B | 111B | 134B | 139B | 136B | 108B |
| Total Liabilities | 73.2B | 82.7B | 68.1B | 64.0B | 44.1B | 40.4B | 48.0B | 54.3B | 51.0B | 27.9B |
| Shareholders' Equity | 43.1B | 50.1B | 54.2B | 69.2B | 65.6B | 70.9B | 86.2B | 84.9B | 84.9B | 80.4B |
| Cash & Short-term Investments | 10.7B | 11.2B | 8.98B | 7.09B | 8.55B | 6.18B | 10.9B | 12.3B | 6.41B | 16.0B |
| Total Debt | 47.9B | 58.0B | 48.0B | 42.3B | 24.9B | 22.2B | 29.3B | 36.5B | 36.1B | 15.6B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 6.50B | 7.02B | 6.00B | 8.26B | 6.83B | 5.37B | 5.52B | 6.23B | 5.16B | 6.87B |
| Capital Expenditure | 2.60B | 8.23B | 3.58B | 2.69B | 3.43B | 2.70B | 3.18B | 5.54B | 5.06B | 2.14B |
| Free Cash Flow | 3.90B | -1.21B | 2.42B | 5.57B | 3.39B | 2.68B | 2.34B | 690M | 104M | 4.73B |
| Ratios | ||||||||||
| ROE | 11.8% | 12.0% | 11.9% | 6.7% | 7.3% | 9.1% | 6.1% | 5.2% | -1.3% | 3.3% |
| ROA | 4.4% | 4.5% | 5.3% | 3.5% | 4.4% | 5.8% | 3.9% | 3.2% | -0.8% | 2.4% |
| Net Profit Margin | 12.4% | 14.1% | 16.6% | 12.1% | 12.7% | 16.8% | 12.8% | 9.9% | -2.5% | 7.6% |
| Debt to Equity | 1.11x | 1.16x | 0.88x | 0.61x | 0.38x | 0.31x | 0.34x | 0.43x | 0.43x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aspen Pharmacare Holdings Ltd dividends
- Dividend yield
- 1.46%
- Forward dividend
- 2.32 ZAC
- Payout ratio
- 35.5%
- Ex-dividend date
- Oct 7, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | ZAR 941M | 2.12 | 35.5% |
| 2025 | ZAR 1.60B | 3.61 | - |
| 2024 | ZAR 1.53B | 3.43 | 34.6% |
| 2023 | ZAR 1.46B | 3.28 | 27.8% |
| 2022 | ZAR 1.20B | 2.64 | 18.4% |
| 2021 | ZAR 1.20B | 2.62 | 24.9% |
| 2020 | ZAR 1.20B | 2.62 | 25.6% |
| 2019 | ZAR 1.44B | 3.15 | 22.2% |
| 2018 | ZAR 1.31B | 2.88 | 21.8% |
| 2017 | ZAR 1.20B | 2.63 | 23.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 407:400 on Oct 6, 2008.
Who owns Aspen Pharmacare Holdings Ltd
- Insiders 20.38%
- Institutions 64.34%
- Public & others 15.29%
- Shares outstanding 433M
- Free float 364M
Aspen Pharmacare Holdings Ltd company profile
- Company name
- Aspen Pharmacare Holdings Ltd
- Ticker
- APN.JSE
- ISIN
- ZAE000066692
- Exchange
- Johannesburg Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7,283
- Fiscal year end
- June
- Address
- Aspen Place, Durban, South Africa
- Phone
- 27 31 580 8600
- Website
- aspenpharma.com
About Aspen Pharmacare Holdings Ltd
Aspen Pharmacare Holdings Limited, together with its subsidiaries, operates as a specialty and branded pharmaceutical company in Africa, the Middle East, Europe, CIS, Australasia, Asia, and the Americas. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers sterile products in injectable form primarily administered in hospitals and prescribed and administered by physicians or in a retail pharmacy environment for therapeutic areas, such as anesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Sandostatin, Sustanon, and Xylocaine brands. It also provides over-the-counter topical products through retail pharmacy and fast-moving consumer goods sectors under the EMLA, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for therapeutic areas, including anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Meticorten brands. In addition, the company manufactures active pharmaceutical ingredients; finished dose form products manufactured for third parties; and heparin-based API to third parties. Further, it exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
Aspen Pharmacare Holdings Ltd management
5- Mr. Stephen Bradley Saad BCom, CA(SA)Group CEO & Executive Director · born 1964
- Mr. Sean M. CapazorioGroup CFO & Executive Director · born 1967
- Ms. Lorraine HillGroup Chief Operations Officer · born 1964
- Mr. Michael Guy Attridge B.Com., CA(SA)Group Chief Advisor · born 1961
- Mr. Reginald Haman Grad. Dip., MBA, ND, NHD, PGDBAConsultant · born 1975